Epivax Oncology is a providence, RI and NY-based precision cancer immunotherapy company.
EpiVax Oncology is a provider of a clinical research and development platform intended to offer various type of precision cancer immunotherapies. The company's platform are based on optimal neo-epitopes selected through its proprietary and validated, in-silico, predictive algorithms, enabling clients to address the unmet medical needs that are inadequately addressed by current cancer therapeutic approaches.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 12, 2018 | Series Unknown | $1.20M | 2 | — | — | Detail |
| May 18, 2018 | Grant | $324.98K | 1 |
National Institutes of Health
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Institutes of Health
|
Yes | Grant |
|
|
— | Series Unknown |
NextWaveBio
|
— | Series Unknown |